SI Money Map · Client

GSK (FKA GLAXOSMITHKLINE INC.) and SI policy

GSK (FKA GLAXOSMITHKLINE INC.) is the client on 7 federal lobbying reports that name SI issues, Q1 2025 to Q3 2026, disclosing $8.9M by the amount rule: $4.8M in 2025 and $4.1M in 2026 so far. It filed 7 reports for itself. Rank 57 of 1,245 clients. Read from LDA.gov, Nov 17, 2026. Amounts are filing totals for all issues on each filing.

Updated Nov 17, 2026Rank 577 SI filings

$8.9MReported, all quarters
7SI filings
7Quarters with filings
8Lobbyist IDs on SI

Over time

Quarter by quarter

Q1 2025 to Q3 2026. Q3 2026 reports were due Oct 20, 2026.

GSK (FKA GLAXOSMITHKLINE INC.): reported amount by quarterBy the amount rule: the in-house report when there is one, else the outside firms' reports.
$0$1M$2MQ1 25: $800KQ2 25: $1.5MQ3 25: $1.7MQ4 25: $810KQ1 26: $1.6MQ2 26: $890KQ3 26: $1.5M$1.7M$1.5MQ1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26$0$1M$2MQ1 25: $800KQ2 25: $1.5MQ3 25: $1.7MQ4 25: $810KQ1 26: $1.6MQ2 26: $890KQ3 26: $1.5M$1.7M$1.5MQ1 25Q3 25Q1 26Q3 26
SI filings and amounts by quarter. Counted: the in-house amount when GSK (FKA GLAXOSMITHKLINE INC.) filed an SI report for itself that quarter, otherwise the outside firms' amounts. Subcontracts are never added.
QuarterFilingsIn-houseOutside firmsCounted
Q3 20261$1,530,000none$1,530,000
Q2 20261$890,000none$890,000
Q1 20261$1,640,000none$1,640,000
Q4 20251$810,000none$810,000
Q3 20251$1,700,000none$1,700,000
Q2 20251$1,510,000none$1,510,000
Q1 20251$800,000none$800,000

The filings

Every SI filing for GSK (FKA GLAXOSMITHKLINE INC.)

Each LD-2 report with at least one issue line that names SI, newest first, with the link to the filing on LDA.gov. "SI lines" shows how many of the filing's issue lines name SI.

Amount: income reported by an outside firm, or expenses reported in-house, for all issues on the filing.
QuarterFiled byAmountSI linesIssue codes and billsSource
Q3 2026Q3, posted Oct 20, 2026
GSK (FKA GLAXOSMITHKLINE INC.)In-house
$1,530,000
2 of 5
Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1492, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269, H.R. 3521, H.R. 4317 ...
Q2 2026Q2, posted Jul 16, 2026
GSK (FKA GLAXOSMITHKLINE INC.)In-house
$890,000
2 of 5
Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269, H.R. 3521 ...
Q1 2026Q1, posted Apr 20, 2026
GSK (FKA GLAXOSMITHKLINE INC.)In-house
$1,640,000
2 of 5
Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269 ...
Q4 2025Q4, posted Jan 20, 2026
GSK (FKA GLAXOSMITHKLINE INC.)In-house
$810,000
2 of 5
Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269 ...
Q3 2025Q3, posted Oct 20, 2025
GSK (FKA GLAXOSMITHKLINE INC.)In-house
$1,700,000
2 of 5
Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269, H.R. 4132 ...
Q2 2025Q2, posted Jul 21, 2025
GSK (FKA GLAXOSMITHKLINE INC.)In-house
$1,510,000
2 of 5
Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269, H.R. 4132 ...
Q1 20251A, posted May 6, 2025
GSK (FKA GLAXOSMITHKLINE INC.)In-house
$800,000
2 of 5
Copyright/Patent/Trademark, Health IssuesH.R. 1262, H.R. 1492, H.R. 1574, H.R. 198, H.R. 2214, H.R. 890, H.R. 946, S. 1040 ...

In their own words

What the filings say

The SI issue lines, quoted as filed: newest first, repeats left out, long lines cut short. The words are the filers'; the filings are public records.

Names as filed
GSK (FKA GLAXOSMITHKLINE INC.)
Issue codes
Copyright/Patent/Trademark (7), Health Issues (7)
Bills named
S. 2658 (9), S. 1040 (7), S. 1041 (7), S. 1095 (7), S. 1096 (7), S. 43 (7), H.R. 1492 (7), H.R. 2214 (7), H.R. 946 (7), S. 832 (7), H.R. 890 (6), S. 1097 (6)
  1. "S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent ..."

    Copyright/Patent/Trademark, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing
  2. "S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. ..."

    Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing
  3. "S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1414: Expedited Access to Biosimilars Act S. 1954: ..."

    Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing
  4. "S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and ..."

    Copyright/Patent/Trademark, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing
  5. "S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - ..."

    Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing
  6. "S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 882: Patients Before Middlemen Act, and other legislation ..."

    Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing
  7. "S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864, HELP Copays Act - A bill to amend title XXVII of the Public Health Service Act to apply financial assistance ..."

    Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing
  8. "S. 705: Innovation in Pediatric Drugs Act of 2025 S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a ..."

    Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing

Embed

Put this card on any page

A plain image that links back here, with its source printed on it. Free under CC BY 4.0. Filings, not influence. The SI Money Map shows what federal disclosure filings report: who paid for lobbying, which issues and bills the filings name, and what super PACs raised and spent. It does not show influence, intent or results, and it takes no side.

Copy the embed
<a href="https://tsio.si/money-map/gsk-fka-glaxosmithkline-inc/"><img src="https://tsio.si/money-map/gsk-fka-glaxosmithkline-inc/card.svg" width="480" height="240" alt="The SI Money Map: GSK (FKA GLAXOSMITHKLINE INC.), $8.9M reported on SI lobbying filings"></a>
SI Money Map card for GSK (FKA GLAXOSMITHKLINE INC.)